Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Daniel Bensen Sells 3,502 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRAGet Free Report) COO Daniel Bensen sold 3,502 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $20.00, for a total transaction of $70,040.00. Following the completion of the transaction, the chief operating officer now owns 427,981 shares in the company, valued at $8,559,620. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Daniel Bensen also recently made the following trade(s):

  • On Friday, June 7th, Daniel Bensen sold 200 shares of Tyra Biosciences stock. The shares were sold at an average price of $20.00, for a total transaction of $4,000.00.

Tyra Biosciences Trading Up 1.1 %

Shares of TYRA stock opened at $20.00 on Tuesday. The stock has a fifty day simple moving average of $17.12 and a two-hundred day simple moving average of $16.03. Tyra Biosciences, Inc. has a 52-week low of $10.38 and a 52-week high of $20.67.

Tyra Biosciences (NASDAQ:TYRAGet Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.11. As a group, research analysts anticipate that Tyra Biosciences, Inc. will post -1.71 earnings per share for the current year.

Hedge Funds Weigh In On Tyra Biosciences

Several hedge funds have recently modified their holdings of TYRA. RA Capital Management L.P. lifted its stake in Tyra Biosciences by 43.9% in the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares in the last quarter. BVF Inc. IL lifted its position in shares of Tyra Biosciences by 70.1% in the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after buying an additional 1,921,599 shares in the last quarter. Kynam Capital Management LP purchased a new stake in shares of Tyra Biosciences in the fourth quarter worth about $4,712,000. Vanguard Group Inc. grew its holdings in Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after buying an additional 140,833 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Tyra Biosciences during the 1st quarter worth approximately $977,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several analyst reports. Oppenheimer reiterated an “outperform” rating and set a $28.00 target price (up from $25.00) on shares of Tyra Biosciences in a research report on Monday, May 13th. Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, May 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Tyra Biosciences in a report on Wednesday, June 5th.

View Our Latest Stock Report on Tyra Biosciences

Tyra Biosciences Company Profile

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Recommended Stories

Insider Buying and Selling by Quarter for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.